Editorial to Driving Ability and Psychotropic Drugs

Gerd Laux; Michael Bauer

doi:10.1055/s-0043-118483

Pharmacopsychiatry, Table of Contents

Pharmacopsychiatry 2017; 50(05): 169-171
DOI: 10.1055/s-0043-118483

Editorial

Editorial to Driving Ability and Psychotropic Drugs

Authors

Gerd Laux

¹Institute of Psychological Medicine, Soyen, Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich, Germany
Michael Bauer

²Department of Psychiatry and Psychotherapy, Carl Gustav Carus University Hospital Dresden, Dresden, Germany

Abstract

Pharmacoepidemiological data show the highly frequent use of psychotropic drugs. According to the „Arzneiverordnungs-Report“ psychotropic drugs range second among the most prescribed medicines in Germany with antidepressants being the dominating class by far [1]. Modern societies demand a high grade of mobility, driving a car is vital for the functional autonomy of patients to take part in activities of daily living and are frequently obligatory for many professions. Psychiatric illness and psychopharmacological treatments may impair driving ability [2] [3] [4] [5] [6]forreview]. Therefore, road safety under psychotropic treatment is of high societal relevance, and the reason for highlighting this rarely covered field of psychopharmacology in this special issue of Pharmacopsychiatry.

Full Text

References

References
1 Schwabe U, Paffrath D. Arzneiverordnungs-Report. Heidelberg: Springer; 2016
2 Brunnauer A, Laux G. Fahrtüchtigkeit und psychische Erkrankung. In: Möller HJ, Laux G, Kapfhammer HP. Hrsg Psychiatrie, Psychosomatik, Psychotherapie. Band 4. 5.Auflage Heidelberg, Berlin: Springer; 2017
3 Brunnauer A, Laux G. Psychopharmaka und Fahrtüchtigkeit. In: Riederer PF, Laux G. Hrsg Grundlagen der Neuro-Psychopharmakologie. Ein Therapiehandbuch. Wien New York: Springer; 2010. p 475-482
4 DRUID Driving under the influence of Drugs, Alcohol and Medicines. 6th Framework Programme. Deliverable 1.1.2b, 4.1.1 http://www.druid-project.eu/Druid/EN/deliverales-list/downloads/Deliverable_1 1 2, 4 1 1.html?nn = 613800 [Accessed 1.8.2017]
5 Dassanayake T, Michie P, Carter G. et al. Effects of benzodiazepines, antidepressants and opioids on driving: A systemic review and meta-analysis of epidemiological and experimental evidence. Drug Saf 2011; 34: 125-156
6 De las Cuevas C, Ramallo Y, Sanz EJ. Psychomotor performance and fitness to drive: The influence of psychiatric disease and its pharmacological treatment. Psychiatry Res 2010; 176: 236-241
7 Brunnauer A, Widder B, Laux G. Grundlagen der Fahreignungsbeurteilung bei neurologischen und psychischen Erkrankungen. Nervenarzt 2014; 85: 805-810
8 Brunnauer A, Laux G. The effects of most commonly prescribed second generation antidepressants on driving ability: A systematic review. J Neural Transm 2013; 120: 225-232
9 Fahrerlaubnisverordnung- FeV (Fassung vom 16.12.2014). http://www.fahrerlaubnisrecht.de/FeV/FeV_Inhaltsverzeichnis.htm [Accessed: 10.07.2017]
10 Gräcmann N, Albrecht M. Begutachtungsleitlinien zur Kraftfahreignung. Bundesanstalt für Straßenwesen. Berichte der Bundesanstalt für Straßenwesen. Mensch und Sicherheit. Heft M115. Bergisch Gladbach 2014
11 Laux G, Brunnauer A. Fahrtauglichkeit bei affektiven Störungen und unter Psychopharmaka. Nervenarzt 2014; 85: 822-828
12 Brunnauer A, Buschert V, Fric M. et al. Driving performance and psychomotor function in depressed patients treated with agomelatine or venlafaxine. Pharmacopsychiatry 2015; 48: 65-71
13 Smink BE, Egberts AC, Lusthof KJ. et al. The relationship between benzodiazepine use and traffic accidents: A systematic literature review. CNS Drugs 2010; 24: 639-653
14 Laar Mv, Volkerts E. Driving and benzodiazepine use. CNS Drugs 1998; 10: 383-396
15 Kawano N, Iwamoto K, Iidaka T. et al. Effects of mild cognitive impairment on driving performance in older drivers. J Am Geriatr Soc 2012; 60: 1379-1381
16 Haussmann R, Wagner T, Müller D. et al. Beurteilung der Fahrtauglichkeit bei Patienten mit MCI und demenziellen Syndromen. Nervenarzt 2017; 88: 247-253
17 Dubinsky R, Stein A, Lyons K. Practice parameters: Risk of driving and Alzheimer‘s disease (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2000; 54: 2205-2211
18 Brunnauer A, Buschert C, Laux G. Demenz und Autofahren. Nervenarzt 2014; 85: 811-815
19 Turk K, Dugan E. Research brief: A literature review of frontotemporal dementia and driving. Am J Alzheimers Dis Other Demen 2014; 29: 404-408
20 Brunnauer A, Laux G, Zwick S. Driving simulator performance and psychomotor functions of patients treated with antipsychotics. Eur Arch Psychiatry Clin Neurosci 2009; 259: 483-489
21 Brunnauer A, Laux G, Geiger E. et al. The impact of antipsychotics on psychomotor performance with regard to car driving skills. J Clin Psychopharmacol 2004; 24: 155-160
22 Kagerer S, Winter C, Möller HJ. et al. Effects of haloperidol and atypical neuroleptics on psychomotor performance and driving ability in schizophrenic patients. Results from an experimental study. Neuropsychobiology 2003; 47: 212-218
23 Soyka M, Winter C, Kagerer S. et al. Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls. J. Psychiatry Res 2005; 33: 101-108
24 Cox DJ, Davis M, Mikami AY. et al. Long-acting methylphenidate reduces collison rates of young adult drivers with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2012; 32: 225-230